Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Kim, Wan Soo ^a   Lee, Sang Soo ^a   Lee, Chang Min ^a   Kim, Hong Jun ^a   Ha, Chang Yoon ^a   Kim, Hyun Jin ^a   Kim, Tae Hyo ^a   Jung, Woon Tae ^a   Lee, Ok Jae ^a   Hong, Jeong Woo ^a   You, Hyun Seon ^a   Cho, Hyun Chin ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Drug induced liver injury; Hepatitis B virus; Hepatitis C virus; Treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; KOREAN (PEOPLE); LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE ANALYSIS; NONHUMAN; ONSET AGE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS; TRANSIENT LIVER FUNCTION IMPAIRMENT; TREATMENT DURATION; UNIVARIATE ANALYSIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; HEPACIVIRUS; MIDDLE AGED; PHYSIOLOGY; SOUTH KOREA; TUBERCULOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84957951064     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1344-2     Document Type: Article

References (32)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62.
2. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol Res. 2005;51(4):353-8.
3. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916-9.
4. van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39(4):488-96.
5. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9(5):534-40.
6. Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med. 2012;185(6):653-9.
7. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-52.
8. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77(4):335-40.
9. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51(2):132-6.
10. Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499-505.
11. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis Drug-Related Liver Dysfunction in Chronic Hepatitis B Infection. Hepatology. 2000;31:201-6.
12. Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892.
13. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1871-6.
14. Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28(1):161-7.
15. Fernandez-Villar A, Sopena B, Garcia J, Gimena B, Ulloa F, Botana M, et al. Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity. Infection. 2007;35(4):295-7.
16. Liu YM, Cheng YJ, Li YL, Liu CE, Hsu WH. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Lung. 2014;192(1):205-10.
17. Lee B-H, Koh W-J, Choi M-S, Suh G-Y, Chung M-P, Kim H-j, et al. Inactive HBsAg carrier state and hepatotoxicity during antiTB chemotherapy. Chest. 2005;127(4):1304-11.
18. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007;131(3):803-8.
19. S-J HWANG, J-C WU, C-N LEE, F-S YEN, C-L LU, T-P LIN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamideinduced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87-91.
20. de Castro L, Do Brasil PE, Monteiro TP, Rolla VC. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis. 2010;14(3):332-40.
21. Un-yeoung G, Hyun-jin S, Yeon-kyeng L, Hyosoon Y, Yoon-sung P, Hae-young K, et al. Annual report on the notified tuberculosis in korea. In: Prevention KCfDC, editor. Korea Centers for Disease Control & Prevention: YANG Byung-guk. 2012. p. 12.
22. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010;53(1):20-8.
23. The Korean Association for the Study of the L. KASL clinical practice guidelines: Management of Hepatitis C. Clin Mol Hepatol. 2014;20(2):89-136.
24. Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31(9):1326-31.
25. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol. 2007;22(3):293-303.
26. Moon H, Lee J. Korean Guidelines for Tuberculosis. Korea: Joint Committee for the Development of Korean Guidelines for Tuberculosis; 2011.
27. WHO: Treatment of tuberculosis guidelines, 4th ed. Geneva, World Health Organization, 2010 (WHO/HTM/STB/2009.420). Available: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.
28. Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A Guide to the Management of Tuberculosis in Patients with Chronic Liver Disease. J Clin Exp Hepatol. 2012;2(3):260-70.
29. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol. 2009;50(1):140-9.
30. Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol. 1999;31(6):1098-105.
31. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
32. Sun H-Y, Chen I-L, Gau C-S, Chang S-C, Luh K-T. A Prospective Study of Hepatitis During Antituberculous Treatment in Taiwanese Patients and a Review of the Literature. J Formos Med Assoc. 2009;108(2):102-11.